December 2021: New work from Alana Welm’s lab reveals a novel immunotherapy target for metastatic breast cancer. A study published in Cancer Discovery shows that blocking short form Ron kinase activity leads to swarming of metastatic lesions by T cells, due to robust expansion of a stem-like CD4+ T helper cell population that continues to fuel the immune response. Ron inhibitors are in clinical development; this finding paves the way for a new immunotherapy strategy in breast cancer.